Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy — TREAT-CDM  

Congenital Myotonic Dystrophy Clinical Trial

Official title: Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy

Status Recruiting

Clinical Trial Summary

Congenital Myotonic Dystrophy (CDM) is a multi-systemic, dominantly inherited disorder caused by a trinucleotide repeat expansion (CTGn) in the DMPK gene. CDM occurs when the CTGn increases between the adult myotonic dystrophy type-1 (DM1) parent and the child. Children with CDM present at birth with respiratory insufficiency, talipes equinovarus, feeding difficulties and hypotonia. There is a 30% mortality rate in the first year of life. As children grow, they are at risk for intellectual impairment, autistic features, gastrointestinal symptoms, and motor delay.

The investigators will enroll children with CDM between ages 0-15 with visits at baseline and one year to evaluate appropriate physical functional outcomes, cognitive function and quality of life over time. Functional outcome measures will be correlated with potential biomarkers in the children. Completion of these specific aims will extend the understanding of disease progression in CDM and will provide the requisite information for successful therapeutic trials in children with DM.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Congenital Myotonic Dystrophy
• Myotonic Dystrophy

• NCT number: NCT03059264
• Study type: Observational [Patient Registry]
• Source: Virginia Commonwealth University
• Contact: Ruby Langeslay, MD
• Phone: 804-828-8481
• Email: ruby.langeslay@vcuhealth.org
• Status: Recruiting
• Start date: December 14, 2016
• Completion date: July 15, 2024